November 22, 2024 - The pCPA Board of Directors is happy to announce the release of the 2023–24 impact report. This report covers an important timeframe for the pCPA, as we transitioned to a stand-alone organization and introduced a new structure with a CEO and board of directors.
The theme, Progress in motion, represents how we successfully navigated that transition and started moving forward fueled by the momentum of our achievements.
Highlights in the report include the estimated dollar savings for public drug plans, calculated at $4.63 billion. This is an increase from an estimated total of $3.89 billion in 2022–23.
The report also shows that overall, the pCPA’s productivity related to negotiations continues to increase compared to pre-pandemic levels. Negotiations are up by more than 50% and we have seen a systematic increase in access to relevant and cost-effective treatments.
Take a look at our 2023–24 impact report to explore the past year and discover what’s ahead for the pCPA.